-The Hindu The CPI leader, in his letter to Jaipal, cites "conflict of interest" Close on the heels of 17 MPs urging Science and Technology Minister Jaipal Reddy to withdraw from the Lok Sabha the recently introduced Biotechnology Regulatory Authority of India (BRAI) Bill, CPI leader D. Raja has also expressed "serious reservations" over the Bill, which provides for a single-window clearance mechanism for genetically modified crops. Urging Mr. Reddy to withdraw the...
More »SEARCH RESULT
Total Matching Records found : 275
Who decides what we eat?-Devinder Sharma
-Tehelka The new Biotechnology Bill will allow biotech firms to tamper with our food In March, US President Barack Obama signed the HR 933 continuing resolution - popularly known as the Monsanto Protection Act - that effectively divests the federal courts of their constitutional power to stop the planting or sale of genetically modified (GM) seeds and crops regardless of the health and environmental consequences. In other words, whether you like...
More »Withdraw BRAI Bill, say 16 MPs
-The Hindu Hyderabad: Sixteen MPs of Opposition parties, have appealed to the Centre to withdraw the Biotechnology Regulatory Authority of India (BRAI) Bill in view of the flaws it had. The MPs pointed to the inherent conflict of interest in the Bill in that it was introduced in Parliament by the Union Ministry of Science and Technology which is also promoting GM crops. The provisions showed limited public participation, no transparency, lack...
More »More battles in store-Aarti Dhar
-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...
More »Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw
-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...
More »
